OBJECTIVES: To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). DESIGN: Cross-sectional. SETTING: Olmsted County, Minnesota. PARTICIPANTS: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11 C-Pittsburgh compound B (11 C-PiB) positron emission tomography (PET) (N=1,782). MEASUREMENTS: We defined an abnormal (high) 11 C-PiB-PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A-) and neurodegeneration (N+/N-). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). RESULTS: Participants with a CDR-SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77-8.67, adjusting for age, sex, education, global cognitive z-score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04-2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A-N + in CU participants. CONCLUSION: The findings of this cross-sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274-2281, 2018.
OBJECTIVES: To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). DESIGN: Cross-sectional. SETTING: Olmsted County, Minnesota. PARTICIPANTS: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11 C-Pittsburgh compound B (11 C-PiB) positron emission tomography (PET) (N=1,782). MEASUREMENTS: We defined an abnormal (high) 11 C-PiB-PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A-) and neurodegeneration (N+/N-). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). RESULTS:Participants with a CDR-SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77-8.67, adjusting for age, sex, education, global cognitive z-score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04-2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A-N + in CUparticipants. CONCLUSION: The findings of this cross-sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274-2281, 2018.
Authors: Gad A Marshall; Lauren E Olson; Meghan T Frey; Jacqueline Maye; J Alex Becker; Dorene M Rentz; Reisa A Sperling; Keith A Johnson Journal: Dement Geriatr Cogn Disord Date: 2011-07-20 Impact factor: 2.959
Authors: Y-L Chang; M W Bondi; L K McEvoy; C Fennema-Notestine; D P Salmon; D Galasko; D J Hagler; A M Dale Journal: Neurology Date: 2011-02-15 Impact factor: 9.910
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen Journal: Alzheimers Dement Date: 2016-09-30 Impact factor: 21.566
Authors: Kamolika Roy; Lesley C Pepin; Marlie Philiossaint; Natacha Lorius; J Alex Becker; Joseph J Locascio; Dorene M Rentz; Reisa A Sperling; Keith A Johnson; Gad A Marshall Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Robert Fieo; Laura Zahodne; Ming X Tang; Jennifer J Manly; Ron Cohen; Yaakov Stern Journal: J Gerontol A Biol Sci Med Sci Date: 2018-11-10 Impact factor: 6.053
Authors: Deborah A Cahn-Weiner; Sarah Tomaszewski Farias; Laura Julian; Danielle J Harvey; Joel H Kramer; Bruce R Reed; Dan Mungas; Margaret Wetzel; Helena Chui Journal: J Int Neuropsychol Soc Date: 2007-05-18 Impact factor: 2.892
Authors: Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen Journal: Brain Date: 2008-02-07 Impact factor: 13.501
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Jee Wook Kim; Min Soo Byun; Bo Kyung Sohn; Dahyun Yi; Eun Hyun Seo; Young Min Choe; Shin Gyeom Kim; Hyo Jung Choi; Jun Ho Lee; Ik Seung Chee; Jong Inn Woo; Dong Young Lee Journal: Psychiatry Investig Date: 2017-07-11 Impact factor: 2.505
Authors: Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Erik D Roberson; Adam Gerstenecker; Roy C Martin; Richard E Kennedy; Daniel C Marson; Ronald C Petersen Journal: Neurol Clin Pract Date: 2022-04
Authors: Juraj Sprung; Mariana Laporta; David S Knopman; Ronald C Petersen; Michelle M Mielke; Toby N Weingarten; Maria Vassilaki; David P Martin; Phillip J Schulte; Andrew C Hanson; Darrell R Schroeder; Prashanthi Vemuri; David O Warner Journal: J Gerontol A Biol Sci Med Sci Date: 2021-09-13 Impact factor: 6.053
Authors: Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Julie A Fields; Yonas E Geda; Jonathan Graff-Radford; David S Knopman; Walter K Kremers; Val Lowe; Mary M Machulda; Michelle M Mielke; Nikki H Stricker; Terry M Therneau; Prashanthi Vemuri; Clifford R Jack Journal: Ann Neurol Date: 2021-04-06 Impact factor: 11.274
Authors: Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Timothy G Lesnick; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Lesley Butler; Martin Traber; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Rosebud O Roberts; Ronald C Petersen Journal: Ann Clin Transl Neurol Date: 2020-04-21 Impact factor: 4.511
Authors: Valory N Pavlik; Samantha C Burnham; Joseph S Kass; Catherine Helmer; Sebastian Palmqvist; Maria Vassilaki; Jean-François Dartigues; Oskar Hansson; Colin L Masters; Karine Pérès; Ronald C Petersen; Erik Stomrud; Lesley Butler; Preciosa M Coloma; Xavier M Teitsma; Rachelle Doody; Mary Sano Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472